Nervenarzt. 2003 Oct;74(10):906-10
Kieseier BC, Gold R, Hartung HP.
Neurologische Klinik, Heinrich-Heine-Universitat Dusseldorf.
The recent publication of the MIMS study (Mitoxantrone in multiple sclerosis), approval by local health authorities, and the recommendation by the MS Therapy Consensus Group (MSTCG) support the use of mitoxantrone in patients with active multiple sclerosis.
This review provides an outline of relevant preclinical and clinical studies, discusses relevant side effects of the compound, and compares its use with other therapeutic approaches to this crippling disorder.